uniQure faces securities fraud lawsuit after FDA approval delay

March 10, 2026 10:17 PM

uniQure N.V. (NASDAQ: QURE) faces a securities fraud class action lawsuit following a significant stock decline after the company disclosed ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found